Dr. Strosberg Discusses Results for KEYNOTE-158

Jonathan R. Strosberg, MD
Published: Monday, Jan 21, 2019



Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the findings from the phase II KEYNOTE-158 trial investigating pembrolizumab (Keytruda) in patients with advanced neuroendocrine tumors (NETs).

The results were not encouraging with only 4 of the 107 patients responding, Strosberg says. All of the responders were PD-L1-negative, concluding that this was not a predictive biomarker. This trial did not show any clear direction in terms of what type of NET will respond tp pembrolizumab treatment.

The data shows that single-agent PD-1/PD-L1 inhibitor is not active in this patient population. Combinations or other options should be looked at in the future, Strosberg concludes.

View more from the 2019 Gastrointestinal Cancers Symposium


Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the findings from the phase II KEYNOTE-158 trial investigating pembrolizumab (Keytruda) in patients with advanced neuroendocrine tumors (NETs).

The results were not encouraging with only 4 of the 107 patients responding, Strosberg says. All of the responders were PD-L1-negative, concluding that this was not a predictive biomarker. This trial did not show any clear direction in terms of what type of NET will respond tp pembrolizumab treatment.

The data shows that single-agent PD-1/PD-L1 inhibitor is not active in this patient population. Combinations or other options should be looked at in the future, Strosberg concludes.

View more from the 2019 Gastrointestinal Cancers Symposium

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x